Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Adimab completes $4mm Series E financing

Executive Summary

OrbiMed Advisors was the lead investor on antibody platform developer Adimab LLC’s $4mm Series E financing. According to the Form D filing, nine other undisclosed backers participated (a secondary industry source reports that all existing shareholders joined, including Google Ventures, Borealis Ventures, Polaris Venture Partners, and SV Life Sciences). The company had a pre-money valuation of $520mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies